SMMT · Summit Therapeutics Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | - | $0 | $0 | $705.0K | $1.81M | $860.0K |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| R&D | $537.67M | $150.78M | $59.47M | $52.00M | $85.35M | $53.27M |
| SG&A | $556.75M | $60.53M | $30.27M | $26.74M | $23.61M | $19.23M |
| Total Operating Expenses | $1.09B | $226.31M | $610.65M | $87.21M | $108.96M | $73.36M |
| D&A | $146.0K | $89.0K | $198.0K | $349.0K | $330.0K | $302.0K |
| Operating Income | ($1.08B) | ($226.00M) | ($609.65M) | ($72.09M) | ($86.19M) | ($53.19M) |
| Interest Expense | $0 | $8.69M | $4.40M | $4.40M | $281.0K | $255.0K |
| Income Tax | $0 | - | - | - | $0 | ($213.0K) |
| Net Income | ($1.08B) | ($221.31M) | ($614.93M) | ($78.78M) | ($88.60M) | ($52.70M) |
| EPS - Basic | ($1.44) | ($0.31) | ($0.99) | ($0.41) | ($0.96) | ($0.76) |
| EPS - Diluted | ($1.44) | ($0.31) | ($0.99) | ($0.41) | ($0.96) | ($0.76) |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $225.27M | $104.86M | $71.42M | $348.61M | $71.79M | $66.42M |
| Accounts Receivable | - | - | $0 | $349.0K | $1.46M | $331.0K |
| Inventory | - | - | - | - | - | - |
| Accounts Payable | $20.29M | $4.64M | $2.67M | $355.0K | $4.37M | $6.14M |
| Current Assets | $720.30M | $423.75M | $189.71M | $656.71M | $97.31M | $87.67M |
| Total Assets | $751.18M | $435.56M | $202.95M | $664.17M | $113.37M | $102.50M |
| Current Liabilities | $72.99M | $41.73M | $20.41M | $38.78M | $25.62M | $19.89M |
| Long-term Debt | - | - | - | - | - | - |
| Total Liabilities | $92.32M | $46.81M | $125.26M | $537.51M | $30.09M | $23.05M |
| Stockholders' Equity | $658.86M | $388.75M | $77.69M | $126.65M | $83.28M | $79.45M |
| Retained Earnings | ($2.29B) | ($1.21B) | ($993.26M) | ($378.33M) | ($299.55M) | ($210.95M) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($322.93M) | ($142.11M) | ($76.76M) | ($41.58M) | ($72.59M) | ($48.11M) |
| Investing Cash Flow | ($174.31M) | ($205.34M) | ($587.77M) | ($624.0K) | ($306.0K) | ($421.0K) |
| Financing Cash Flow | $617.53M | $381.23M | $86.51M | $620.24M | $77.92M | $50.55M |
| CapEx | $657.0K | $139.0K | $128.0K | $624.0K | $306.0K | $421.0K |
| Free Cash Flow | ($323.59M) | ($142.25M) | ($76.89M) | ($42.21M) | ($72.89M) | ($48.53M) |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | - | - | - | - | - | - |
| Operating margin | - | - | - | -10225.4% | -4764.3% | -6185.2% |
| EBITDA margin | - | - | - | -10175.9% | -4746.0% | -6150.1% |
| Net margin | - | - | - | -11174.8% | -4897.8% | -6127.6% |
| Free cash flow margin | - | - | - | -5986.7% | -4029.5% | -5643.3% |
| FCF / Net income | 0.30 | 0.64 | 0.13 | 0.54 | 0.82 | 0.92 |
| R&D / Revenue | - | - | - | 7375.7% | 4718.2% | 6194.7% |
| SG&A / Revenue | - | - | - | 3793.3% | 1305.2% | 2236.3% |
| Effective tax rate | - | - | - | - | - | - |
| Return on assets | -143.7% | -50.8% | -303.0% | -11.9% | -78.2% | -51.4% |
| Return on equity | -163.9% | -56.9% | -791.5% | -62.2% | -106.4% | -66.3% |
| Return on invested capital | - | - | - | - | - | - |
| Liquidity | ||||||
| Current ratio | 9.87 | 10.15 | 9.30 | 16.93 | 3.80 | 4.41 |
| Quick ratio | 9.87 | 10.15 | 9.30 | 16.93 | 3.80 | 4.41 |
| Cash ratio | 3.09 | 2.51 | 3.50 | 8.99 | 2.80 | 3.34 |
| Leverage | ||||||
| Debt / Equity | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | - | -26.0x | -138.5x | -16.4x | -306.7x | -208.6x |
| Equity multiplier | 1.14 | 1.12 | 2.61 | 5.24 | 1.36 | 1.29 |
| Liabilities / Assets | 0.12 | 0.11 | 0.62 | 0.81 | 0.27 | 0.22 |
| Efficiency | ||||||
| Asset turnover | - | 0.00 | 0.00 | 0.00 | 0.02 | 0.01 |
| Inventory turnover | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | 181d | 295d | 140d |
| Days inventory outstanding | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | 19.8x | 33.0x | 20.8x | 6.5x | 3.0x | 4.1x |
| P / S | - | - | - | 1165.5x | 137.2x | 380.0x |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | - | - | -100.0% | -61.0% | 110.3% | - |
| Revenue CAGR (3y) | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - |
| Operating income growth (YoY) | -377.7% | 62.9% | -745.7% | 16.4% | -62.0% | - |
| Net income growth (YoY) | -387.8% | 64.0% | -680.5% | 11.1% | -68.1% | - |
| EPS growth (YoY) | -364.5% | 68.7% | -141.5% | 57.3% | -26.3% | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | -127.5% | -85.0% | -82.2% | 42.1% | -50.2% | - |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | 69.5% | 400.4% | -38.7% | 52.1% | 4.8% | - |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2022-12-31.
Product / service
$705.0K totalLicense And Service$705.0K · 100.0%
Geographic
$705.0K totalLatin America$705.0K · 100.0%
Stability scores
Piotroski F-score
FY 2025 · 9-point quality
1/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✗Current ratio improved
- ✗No share dilution
- -Gross margin improved
- -Asset turnover improved
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Summit Therapeutics Inc. against the 5 most active filers in the same SIC group.